Covid-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Vial Remdesivir 100 mg Ronak Pharmaceutical Company for 5 days, 200 mg on the first day and 100 mg on the second to fifth days
Levofloxacin 750 mg tablets Abidi Pharmaceutical Company for 5 days, 750 mg daily
Vial Ceftriaxone 1 gr Exir Pharmaceutical for 5 days, 1 gr every 12 hours
. Intervention 2: Control group: Vial Remdesivir 100 mg Ronak Pharmaceutical Company for 5 days, the first day 200 mg and the second to fifth days 100 mg.
Sponsors
Shahre-kord University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Patients with confirmed molecular test (PCR positive) Blood oxygen saturation level SpO2 <93% in room air Patients with moderate pulmonary involvement in radiological studies No need for antibiotics in terms of indicator bacterial infection (PCT negative)
Exclusion criteria
Exclusion criteria: Patient dissatisfaction with participation in the study Need for antibiotics according to the indication of bacterial infection (PCT positive)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Erythrocyte Sedimentation rate. Timepoint: Measurement of erythrocyte sedimentation rate on the first and seventh days. Method of measurement: Measurement of erythrocyte sedimentation rate by the device ESR analyzer semimex.;C-reactive protein. Timepoint: Measurement of C-reactive protein on the first and seventh days. Method of measurement: Measurement of C-reactive protein with the device BT-3500 And BT-3000.;Ferritin. Timepoint: Measurement of ferritin on the first and seventh day. Method of measurement: Measurement of ferritin with the device Cobas. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAhmad Raesi
Shahre-kord University of Medical Sciences
Outcome results
None listed